Insulin resistance slows weight loss rather than preventing it. In the guides we publish here, the version of this question that arrives most often is from someone who held a calorie deficit for eight weeks, saw the scale barely move, and concluded their metabolism is broken.
High circulating insulin does suppress fat release from adipose tissue, so the same deficit returns a smaller weekly change than it would in someone insulin sensitive. That is a real handicap. It is a slower rate rather than a locked door, and several trials have now tested the stronger claim and failed to support it.
The Verdict
What Insulin Resistance Does to Body Weight
Insulin is a storage signal. When it is high, adipose tissue takes up fatty acids and releases fewer of them, which is the physiology behind the observation that fat loss is harder against a background of hyperinsulinaemia.
The popular account overstates the size of that effect. Insulin resistance changes the rate of fat loss for a given deficit. It does not suspend energy balance, and it does not stop the deficit working. People with type 2 diabetes lose weight in every trial that puts them in a deficit, including the ones that produced remission.
Our page on fasting insulin covers what the underlying number represents and why most standard panels leave it out.
The Direction of Cause Runs Mostly the Other Way
Visceral fat drives insulin resistance more reliably than insulin resistance drives visceral fat. That tissue sits around the organs, releases free fatty acids and inflammatory signals into the portal circulation reaching the liver, and raises insulin demand directly.
This ordering has a practical consequence. If insulin resistance were the primary cause, the right move would be to fix insulin first and let weight follow. Because abdominal fat is doing most of the driving, reducing it improves insulin sensitivity quickly, and the improvement shows up before the scale reaches any particular number. Our guide to visceral fat covers how it is measured and why waist circumference outperforms body mass index for this question.
Both directions operate at once, which is why the loop is hard to break from either end and responds well when you push on both.
Why the Scale Stalls While the Markers Improve
Three things move at different speeds during the first two months, and only one of them is body weight.
- Liver fat falls first. A calorie deficit or a carbohydrate reduction lowers hepatic fat within the first weeks, and hepatic insulin sensitivity improves alongside it. Fasting insulin often drops before total weight has changed much.
- Glycogen and water shift early and then stop. The rapid first-week drop on a carbohydrate reduction is mostly stored glycogen and the water bound to it, which is why week three looks like a stall against a week one that was never fat loss.
- Muscle gain can hold the scale still. Resistance training during a deficit adds muscle while fat is lost, which is a better outcome than the scale reports.
Tracking waist circumference weekly and fasting insulin at six weeks gives a more accurate read of what is happening than daily weighing during this window. Our page on HOMA-IR covers how to turn insulin and glucose from one draw into a single trackable index.
Where GLP-1 Medication Fits
GLP-1 receptor agonists changed what is achievable here, and they are frequently described in terms that overstate what they do to insulin resistance specifically.
| Medication | How it works | What the trials showed | The trade-off |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | GLP-1 receptor agonist, weekly injection | About 15 percent average body weight reduction at 68 weeks in the STEP 1 trial | Nausea and other gastrointestinal effects are the common reason for stopping. Weight is largely regained after discontinuation |
| Tirzepatide 15 mg (Zepbound) | Dual GIP and GLP-1 receptor agonist, weekly injection | About 21 percent average body weight reduction at 72 weeks in the SURMOUNT-1 trial | Same gastrointestinal profile, and the same regain pattern on stopping. Higher cost in most markets |
| Metformin | Reduces hepatic glucose output and improves insulin sensitivity, daily tablet | Modest weight effect, typically 2 to 3 kg, alongside a measurable improvement in insulin markers | Cheap and long-established. It is a metabolic drug that happens to help weight slightly, rather than a weight drug |
Semaglutide is made by Novo Nordisk and sold as Wegovy for weight management and Ozempic for type 2 diabetes. Tirzepatide is made by Eli Lilly and sold as Zepbound and Mounjaro. Both improve insulin markers, and the improvement tracks the weight lost rather than arriving through a separate mechanism acting on insulin sensitivity.
That distinction determines what happens when the medication stops. The STEP 1 trial extension followed participants after semaglutide withdrawal and found around two thirds of the lost weight returned within a year. Insulin markers drifted back with it. Anyone starting one of these drugs should agree the long-term plan with their prescriber at the start.
What to Do Before Adding a Medication
Four things have a large effect and no prescription requirement. They are worth exhausting first, partly because they are what makes the medication work better if you do add it.
- Resistance training twice a week. Skeletal muscle handles most post-meal glucose, and training raises that capacity independently of weight change.
- Protein at every meal. It protects muscle during a deficit and lowers the glucose response to the same meal. Our protein timing guide covers the distribution evidence.
- Sleep of adequate length. A few nights of short sleep reduce insulin sensitivity measurably in controlled studies, and no deficit compensates for it.
- Removing liquid sugar. Sugar-sweetened drinks and juice arrive without fibre or protein to slow absorption, which makes them the largest insulin pulse per calorie in most diets.
Our insulin resistance diet page covers the eating patterns with trial evidence behind them, and the prediabetes reversal guide covers what to do if glucose has already crossed a threshold.
Who Should Not Take This Route
Three groups need a different approach.
- Anyone with a history of an eating disorder. Calorie tracking, weekly weighing and food restriction are poor tools here. Resistance training and sleep are the parts of this page that still apply.
- Anyone taking insulin or a sulfonylurea. Cutting carbohydrate or calories while medication doses stay unchanged risks hypoglycaemia, so dose review comes first.
- Anyone whose weight is stable and whose markers are already optimal. Pursuing further loss for a metabolic reason that does not exist has costs, particularly loss of muscle mass in later life.
Our reading would change if a trial showed GLP-1 medication improving insulin sensitivity independently of weight loss, at a size that mattered. Current evidence ties the metabolic improvement to the weight change, which is why discontinuation is such a problem. A drug that improved insulin signalling directly would justify a different sequence, with medication earlier rather than after three months of unsuccessful effort.
Book a fasting insulin test now and repeat it at six weeks, so your next decision about insulin resistance and weight loss rests on a number rather than on what the scale did this morning.
Frequently Asked Questions
Does insulin resistance make you gain weight?
The relationship runs mostly the other way. Visceral fat is metabolically active tissue that raises insulin demand, so weight gain around the abdomen drives insulin resistance more reliably than insulin resistance drives weight gain. High circulating insulin does favour fat storage over fat release, which makes the process harder to interrupt once it is running. Treating insulin resistance as the sole cause of weight gain leads people to look for a metabolic fix when the intervention with the largest effect is still reducing visceral fat.
Why can I not lose weight with insulin resistance?
Weight loss is slower with insulin resistance, and it is not blocked. The DIETFITS trial randomised over 600 adults to low-fat or low-carbohydrate diets and found that baseline insulin secretion did not predict who lost more weight on which diet. What does change is the rate: high circulating insulin suppresses fat release from adipose tissue, so the same calorie deficit produces a smaller weekly change. Extending the timeline and protecting muscle mass matters more here than switching diets again.
Does losing weight reverse insulin resistance?
Losing visceral fat improves insulin sensitivity reliably, and the effect appears well before the scale reaches a target. In the DiRECT trial, sustained weight loss produced type 2 diabetes remission in 46 percent of participants at 12 months. Improvement starts early: liver fat falls within the first weeks of a calorie deficit, and hepatic insulin sensitivity improves alongside it. That is why fasting insulin often moves before body weight has changed much at all.
Do GLP-1 drugs treat insulin resistance?
They improve insulin sensitivity mainly through the weight loss they produce, rather than through a direct effect on how cells respond to insulin. Semaglutide and tirzepatide both lower HbA1c and fasting insulin in trials, and the size of that improvement tracks the amount of weight lost. This distinction matters when the medication stops: insulin markers drift back with the weight, which is why these are treated as ongoing therapy rather than as a course of treatment.
Will I regain the weight if I stop Ozempic or Zepbound?
Most people do. The STEP 1 extension study followed participants after semaglutide was withdrawn and found they regained around two thirds of the lost weight within a year. Tirzepatide withdrawal trials show a similar pattern. The practical implication is that these drugs are prescribed as long-term therapy for weight management. Anyone starting one should discuss the exit plan with their prescriber at the beginning rather than at the point of stopping.
Should I lift weights or do cardio for insulin resistance?
Both help, and resistance training does something cardio does not. Skeletal muscle disposes of most post-meal glucose, and resistance training increases both the amount of muscle and its capacity to take glucose up, independently of weight change. That makes it the intervention that works when the scale is not moving, and the one that protects against losing muscle during a calorie deficit. Aerobic work improves insulin sensitivity too, and the combination outperforms either alone in trials.
Why did my fasting insulin improve but my weight stay the same?
This is a common and encouraging pattern. Liver fat falls quickly on a calorie deficit or a carbohydrate reduction, and hepatic insulin sensitivity improves alongside it before total body weight has changed much. Resistance training adds muscle while fat is being lost, which can hold the scale still while body composition changes underneath. Judging progress on fasting insulin, waist circumference and how your clothes fit gives a more accurate picture than weight alone during the first two months.
Does insulin resistance cause belly fat specifically?
Abdominal fat and insulin resistance track together closely, and the causation runs in both directions. Visceral fat releases free fatty acids and inflammatory signals directly into the portal circulation reaching the liver, which worsens hepatic insulin sensitivity. High insulin in turn favours storage in that depot. Waist circumference is a better rough indicator of the relevant fat than body mass index, which is why it appears in metabolic syndrome criteria and body weight alone does not.
Related
- Insulin resistance diet: the patterns with trial evidence
- Visceral fat: the tissue driving the loop
- Fasting insulin: the marker to track this on
- Insulin resistance vs prediabetes: two different measurements
- Prediabetes reversal: the targets that work
- Zone 2 cardio: the aerobic side of glucose disposal
- Continuous glucose monitoring: meal-level feedback while you change things